Projects per year
Personal profile
Education
- 1983 MD, College of Medicine, National Taiwan University
Research Interests
- Cell Signaling Transduction
- Nanomedicine
- Oncology
- Clinical Trial
Experience
- 2004/08~now Professor, Department of Internal Medicine, College of Medicine, National Cheng Kung University
- 2017/08~now Director, Department of Internal Medicine, National Cheng Kung University Hospital
- 2004/07~now Chief, Division of Hematology/Oncology, Department of Internal Medicine, National Cheng Kung University Hospital
- 1990/08~now Attending Physician, National Cheng Kung University Hospital
- 2011/10~2017/07 Director, Cancer Center, National Cheng Kung University Hospital
- 2006/01~2011/09 Director, Clinical Trial Center, National Cheng Kung University Hospital
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Fingerprint
Dive into the research topics where Wu-Chou Su is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Research output
-
Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial
Lu, S., Wang, Q., Zhang, G., Dong, X., Yang, C. T., Song, Y., Chang, G. C., Lu, Y., Pan, H., Chiu, C. H., Wang, Z., Feng, J., Zhou, J., Xu, X., Guo, R., Chen, J., Yang, H., Chen, Y., Yu, Z., Shiah, H. S. & 22 others, , 2022 Mar, In: Journal of Thoracic Oncology. 17, 3, p. 411-422 12 p.Research output: Contribution to journal › Article › peer-review
Open Access9 Citations (Scopus) -
Improved survival in patients with unresectable stage III EGFR-mutant adenocarcinoma with upfront EGFR-tyrosine kinase inhibitors
Wang, S. Y., Lai, C. H., Chen, C. W., Yang, S. C., Chang, C. C., Lin, C. Y., Yen, Y. T., Tseng, Y. L., Su, P. L., Lin, C. C. & Su, W. C., 2022 Jan, In: Thoracic Cancer. 13, 2, p. 182-189 8 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Targeting protumor factor chitinase-3-like-1 secreted by Rab37 vesicles for cancer immunotherapy
Yang, P. S., Yu, M. H., Hou, Y. C., Chang, C. P., Lin, S. C., Kuo, I. Y., Su, P. C., Cheng, H. C., Su, W. C., Shan, Y. S. & Wang, Y. C., 2022, In: Theranostics. 27, 1, p. 340-361 22 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Biocompatible hole scavenger-assisted graphene oxide dots for photodynamic cancer therapy
Shih, C. Y., Huang, W. L., Chiang, I. T., Su, W. C. & Teng, H., 2021 May 14, In: Nanoscale. 13, 18, p. 8431-8441 11 p.Research output: Contribution to journal › Article › peer-review
3 Citations (Scopus) -
Cd40 pathway and il-2 expression mediate the differential outcome of colorectal cancer patients with different csf1r c.1085 genotypes
Yeh, Y. M., Lin, P. C., Su, W. C. & Shen, M. R., 2021 Nov 1, In: International journal of molecular sciences. 22, 22, 12565.Research output: Contribution to journal › Article › peer-review
Open Access